Dr. Marin attended The Mount Sinai School of Medicine and the Mount Sinai Psychiatry Residency. Upon completion of her Residency, Dr. Marin completed a research fellowship in mood disorders at Cornell Medical College. Since her return to Mount Sinai in 1992, Dr. Marin has held several leadership positions, including Chief of Geriatric Psychiatry, Medical Director of the Department of Psychiatry, Dean for Clinical Research, and Chief Medical Officer. At Mount Sinai, Dr. Marin’s research focus has been is in the area of memory disorders. She has been principal investigator in NIH funded grants that have investigated the clinical and biological correlates of normal aging and dementia. She has published several articles related to these topics. Dr. Marin’s clinical interests include the treatment of memory disorders and depression. Dr. Marin’s teaching interests are not only in the area of Psychiatry but also in the area of improving physician patient.
Financial & Billing Information
Please direct any detailed billing or financial inquires to the Mount Sinai Psychiatry billing customer service number at 212-659-8752.
Psychiatry, American Board of Psychiatry and Neurology
MD, Mount Sinai Sch. of Medicine CUNY
Mount Sinai Hospital
Cornell University Medical College
New York Magazine
New York Magazine
Haroutunian V, Serby M, Purohit DP, Perl DP, Marin D, Lantz M, Mohs RC, Davis KL. Contribution of Lewy body inclusions to dementia in patients with and without Alzheimer disease neuropathological conditions. Arch Neurol 2000; 57(8): 1145-1150.
Haroutunian V, Purohit DP, Perl DP, Marin D, Kahn K, Lantz M, Davis KL, Mohs RC. Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. Arch Neurol 1999; 56(6): 713-718.
Davis KL, Mohs RC, Marin DB, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V. Neuropeptide abnormalities in patients with early Alzheimer disease. Arch Gen Psychiatry 1999; 56(11): 981-987.
Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 1999; 28(15): 1401-1406.
Haroutunian V, Perl DP, Purohit DP, Marin D, Kahn K, Lantz M, Davis KL, Mohs RC. Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch Neurol 1998; 55(9): 1185-1191.
Marin DB, Breuer B, Marin ML, Silverman J, Schmeidler J, Greenberg D, Flynn S, Mare M, Lantz M, Libow L, Neufeld R, Altstiel L, Davis KL, Mohs RC. The relationship between alipoprotein E, dementia, and vascular illness. Atherosclerosis 1998; 140(1): 173-180.
Marin DB, Green CR, Schmeidler J, Harvey PD, Lawlor BA, Ryan TM, Aryan M, Davis KL, Mohs RC. Noncognitive disturbances in Alzheimer’s disease: frequency, longitudinal course, and relationship to cognitive symptoms. J Am Geriatr Soc 1997; 45(11): 1331-1338.
Davis KL, Marin DB, Kane R, Patrick D, Peskind ER, Raskind MA, Puder KL. The Caregiver Activity Survey (CAS): development and validation of a new measure for caregivers of persons with Alzheimer’s disease. International Journal of Geriatric Psychiatry 1997; 12(10): 978-988.
Altstiel LD, Greenberg DA, Marin D, Lantz M, Mohs R. Alipoprotein E genotype and cognition in the very old. The Lancet 1997; 349(9063): 1451.
Marin DB, Kocsis JH, Frances AJ, Parides M. Desipramine for the treatment of “pure” dysthymia versus “double” depression. The American Journal of Psychiatry 1994; 151(7): 1079-1080.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Marin did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.